Abstract
Nine transfusion-dependent β-thalassaemia major patients (seven males and two females), aged 4–15 years, with growth retardation and severe rickets-like radiological lesions due to continuous subcutaneous chelation therapy with desferrioxamine (45–75 mg/kg body weight, 6–7 times/week), were seen in our centre during the last 8 years. Serum ferritin levels ranged from 976 to 4115 μg/l. There was a progressive decline in growth velocity in these patients 2–3 years before the appearance of rickets-like radiological lesions. All patients underwent surgery to correct genu valgum and/or slipped capital epiphyses. The final height was below the 3rd percentile in six patients (SDS: from −2.9 to −5.2). The short stature was mainly due to a disproportion between upper and lower segments. Six of the patients had an associated sensorineural hearing loss.
Conclusion
Our data emphasize the importance of an accurate surveillance of the toxic effects of desferrioxamine treatment and warn of the risk of overtreating patients with low iron overload and also suggest a possible individual idiosyncrasy to the adverse effects of chelation therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- DFX :
-
desferrioxamine
- IRMA :
-
immunoradiometric assay
References
Arden GB, Wonke B, Kennedy C, Huehns ER (1984) Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophtalmol 68:873–877
Brill PW, Winchester P, Giardina PI, Cunnigham-Rundles S (1991) Desferrioxamine induced bone dysplasia in patients with thalassaemia major. A J R 156:561–565
Cohen A, Martin M, Schwartz E (1984) Depletion of excessive liver iron stores with desferrioxamine. Br J Haematol 58:369–373
Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER (1984) Ocular toxicity of high dose intravenous desferrioxamine. Lancet II:181–184
De Sanctis V, Katz M, Vullo C, Bagni B, Ughi M, Wonke B (1994) Effect of different treatment regimes on linear growth and final height in β-thalassaemia major. Clin Endocrinol 40:791–798
De Virgilis S, Argiolu F, Sanna G, Cornacchia G, Cossu P, Cao A, Mallardi V, Puxcddu P (1979) Auditory involvement in thalassaemia major. Acta Haematol 61:209–213
De Virgilis S, Congia M, Frau F, Argiolu F, Diana G, Cucca F, Varsi A, Sanna G, Podda G, Fodde M, Pirastu GF, Cao A (1988) Desferrioxamine-induced growth retardation in patients with thalassemia major. J Pediatr 113:661–669
Elena MG, Fedele A, Gianino P, Giordanino S, Murru P, Tosi C, Vanelli S (1992) Velocità di crescita dei bambini talassemici sottoposti a diversi protocolli di terapia chelante. Min Pediatr 44:41–42
Fosburg MT, Nathan DG (1990) Treatment of Cooley's anemia. Blood 76: 435–444
Lankhanpal V, Schocket SS, Jiji R (1986) Desferrioxamine induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology 91:443–451
Llados I, Vallory EA, Girot R, Lenoir G, Payet M, Houze P, Bourden R (1989) Studies of variations of subcutaneusly infused desferrioxamine and iron movements in thalassaemia children. Eur J Pediatr 148:503–506
Olivieri NF, Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N, Looan W, Mitchell D, Ricci G, Skarf B, Taylor M, Freedman M (1986) Visual and auditory neurotoxicity in patients receiving subcutaneous desferrioxamine infusion. N Engl J Med 314:869–873
Olivieri NF, Koren G, Harris J, Khattak S, Freedman M, Templeton DM, Bailey JD, Reilly BJ (1992) Growth failure and bony changes induced by desferoxamine. Am J Pediatr Hematol/Oncol 14(1):48–56
Olivieri NF, Nathan DG, Mac Millan JH, Wayne AS, Liu PP, Mc Gee A, Martin M, Koren G, Cohen AR (1994) Survival in medically treated patients with homozygous β-thalassaemia. N Eng J Med 331:574–578
Porter JB, Jaswon MS, Huhens ER, East CA, Jonathan WP (1989) Desferrioxamine ototoxicity: evaluation of risk factors in thalassemic patients and guidelines for safe dosage. Br J Haematol 73:403–409
Rebulla P, Modell B (1991) Transfusion requirements and effects in patients with thalassaemia major. Lancet 337:277–280
Summers MR, Jacobs A, Tudway D, Perera P, Ricketts C (1979) Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br J Haematol 42:547–555
Tanner JM (1978) Physical growth and development. In: Forfar JD, Arneil GC (eds) Textbook of paediatrics. Second edition. Livingston, Edinburgh, pp 287–290
Weatherall DJ, Clegg JG (1981) The thalassaemia syndromes. Third edition. Blackwell Scientific Publication, Oxford
Wolfe L, Olivieri N, Sallan D, Olan S, Rose W, Propper R, Freedman M, Nathan D (1985) Prevention of cardiac disease by subcutaneous desferrioxamine in patients with thalassemia major. N Engl J Med 312:1600–1603
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
De Sanctis, V., Pinamonti, A., Di Palma, A. et al. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine. Eur J Pediatr 155, 368–372 (1996). https://doi.org/10.1007/BF01955263
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01955263